Premium
Chlorpheniramine inhibits the ornithine decarboxylase induction of Ehrlich carcinoma growing in vivo
Author(s) -
Urdiales J.L.,
Matés J.M.,
de Castro I.Núñez,
Sánchez-Jiménez F.M.
Publication year - 1992
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(92)80682-7
Subject(s) - ornithine decarboxylase , in vivo , ornithine , transplantation , inoculation , chemistry , microbiology and biotechnology , inhibitory postsynaptic potential , pharmacology , biology , cancer research , medicine , biochemistry , immunology , endocrinology , enzyme , genetics , amino acid , arginine
The antihistaminic (±)‐chlorpheniramine significantly reduced the progression of Ehrlich carcinoma when it was administered at 0.5 mg/mouse/day from the third day on, after tumour inoculation. The ODC activity of tumour cells was diminished by 70% on day 7 after tumour transplantation, when maximum ODC activity is detected in non‐treated tumour growing ‘in vivo’. Northern blot analyses indicated that the inhibitory effect of this 1,4‐diamine takes place at a post‐transcriptional level. Results obtained from serum‐free cultured cells indicated that chlorpheniramine inhibits the ODC synthesis rate.